Trastuzumab deruxtecan binds HER2, is internalized, and releases the DXd topoisomerase I inhibitor, causing DNA damage, replication arrest, and apoptosis in HER2-expressing cells; it can also induce ADCC and a membrane-permeable bystander killing effect.